Unfortunately, the role for MAO in the context of AD progression is not likely to be as straightforward as anticipated given that Roche recently terminated a clinical trial centered on sembragiline, a highly selective MAO-B inhibitor, because of a lack of amelioration of the Alzheimer’s Disease Assessment Scale-Cognitive Behavior Subscale2. The gene discussed is MAOB; the disease is Alzheimer disease.